Insider Buying: FocalTherics (NASDAQ:FOCL) CFO Acquires $23,750.00 in Stock

FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $4.75 per share, with a total value of $23,750.00. Following the purchase, the chief financial officer owned 181,610 shares of the company’s stock, valued at $862,647.50. The trade was a 2.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

FocalTherics Trading Up 2.3%

Shares of FocalTherics stock opened at $4.36 on Thursday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.60. The firm has a fifty day moving average of $5.37. The firm has a market cap of $163.41 million, a PE ratio of -4.23 and a beta of -0.04. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million for the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. On average, analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday. Finally, Mizuho set a $15.00 price target on FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.75.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. SmartHarvest Portfolios LLC acquired a new stake in FocalTherics in the first quarter valued at about $38,000. Lido Advisors LLC purchased a new stake in FocalTherics in the 1st quarter valued at approximately $40,000. Kovack Advisors Inc. acquired a new position in FocalTherics during the 4th quarter worth approximately $53,000. Rock Springs Capital Management LP increased its position in FocalTherics by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after purchasing an additional 16,500 shares during the period. Finally, Leonteq Securities AG purchased a new position in shares of FocalTherics during the 4th quarter worth approximately $313,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.